DCLK1 and cancer: Targeting Dclk1 with siDCLK1-NPs reduces the dysregulation in miRNAs, EMT, and pluripotency associated with cancer risk, suggesting that targeting Dclk1 in patients even with advanced cancer may be a therapeutic option for intestinal and/or other solid tumors.